IDEXX Laboratories Inc (IDXX) reports robust revenue growth driven by diagnostics and consumables, despite facing headwinds ...

Shares of IDEXX Laboratories, Inc. (IDXX) traded 9% higher on Thursday afternoon after the company reported upbeat ...

IDEXX reaffirmed its 2025 full-year goals, projecting organic revenue growth between 6% and 9% and comparable operating margin improvement. Updated guidance for reported revenues now ranges from ...

Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay ...

Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and ...

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.

The Animal diagnostic and health care company posted revenue of $998.4 million in the period, which missed Street forecasts. Six analysts surveyed by Zacks expected $1.02 billion. Idexx expects ...

HOLX has an Earnings ESP of 0.00% and carries a Zacks Rank #3. IDEXX: In the first quarter of 2025, the company is likely to ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Idexx Laboratories (IDXX ... it's worth handicapping the probability of a positive EPS surprise. This Animal diagnostic and health care company is expected to post quarterly earnings of $2. ...

"With advances in experimental diagnostics, technology and computing, we are now at a point where we can understand it because we have these new tools," Khare said. But there is still much to explore.